These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32595697)

  • 1. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
    Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
    Front Genet; 2020; 11():534. PubMed ID: 32595697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
    Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
    J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma.
    Zhang D; Duan Y; Cun J; Yang Q
    Front Genet; 2019; 10():278. PubMed ID: 30984247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of alternative splicing events and prognostic signatures in breast cancer.
    Han P; Zhu J; Feng G; Wang Z; Ding Y
    BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Alternative mRNA Splicing Signature and a Novel Biomarker in Triple-Negative Breast Cancer.
    Liu Q; Wang X; Kong X; Yang X; Cheng R; Zhang W; Gao P; Chen L; Wang Z; Fang Y; Wang J
    DNA Cell Biol; 2020 Jun; 39(6):1051-1063. PubMed ID: 32379494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
    Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
    J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer.
    AZhaTi B; Wu G; Zhan H; Liang W; Song Z; Lu L; Xie Q
    World J Surg Oncol; 2022 Jul; 20(1):231. PubMed ID: 35820925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma.
    Duan Y; Zhang D
    J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Functional Impact of Alternative Splicing on the Survival Prognosis of Triple-Negative Breast Cancer.
    Wu S; Wang J; Zhu X; Chyr J; Zhou X; Wu X; Huang L
    Front Genet; 2020; 11():604262. PubMed ID: 33519909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
    Zhang D; Duan Y; Wang Z; Lin J
    Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
    Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
    Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potential key genes and pathways predicting pathogenesis and prognosis for triple-negative breast cancer.
    Lv X; He M; Zhao Y; Zhang L; Zhu W; Jiang L; Yan Y; Fan Y; Zhao H; Zhou S; Ma H; Sun Y; Li X; Xu H; Wei M
    Cancer Cell Int; 2019; 19():172. PubMed ID: 31297036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data.
    Zhang D; Zhang W; Sun R; Huang Z
    Bioengineered; 2021 Dec; 12(1):1091-1110. PubMed ID: 33783315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of survival-related alternative splicing signatures in acute myeloid leukemia.
    Zhang B; Yang L; Wang X; Fu D
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34212178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of prognostic alternative splicing signatures in uveal melanoma.
    Xie X; Zheng X; Xie T; Cai J; Yao Y
    Int Ophthalmol; 2021 Apr; 41(4):1347-1362. PubMed ID: 33479809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma.
    Sun JR; Kong CF; Lou YN; Yu R; Qu XK; Jia LQ
    Front Genet; 2020; 11():796. PubMed ID: 32793288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of DNA Damage Repair Genes Involved in the Prognosis of Triple-Negative Breast Cancer Patients Based on Bioinformatics.
    Wang N; Gu Y; Chi J; Liu X; Xiong Y; Zhong C; Wang F; Wang X; Li L
    Front Genet; 2021; 12():721873. PubMed ID: 34408776
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
    Lai J; Yang H; Xu T
    BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
    Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
    J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.